Evidence map›Paper›PMID 30943188›Full record

ArticlePloS one2019

A vascular smooth muscle cell X-box binding protein 1 and transglutaminase 2 regulatory circuit limits neointimal hyperplasia.

Ramon L Serrano, Weifang Yu, Robert M Graham, Ru Liu- Bryan, Robert Terkeltaub

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Exercise and Asthma.Advances in experimental medicine and biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ramon L SerranoDepartment of Medicine, Veterans Affairs Healthcare System, University of California San Diego, California, United States of America.
Weifang YuDepartment of Medicine, Veterans Affairs Healthcare System, University of California San Diego, California, United States of America.
Robert M GrahamVictor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
Ru Liu- BryanDepartment of Medicine, Veterans Affairs Healthcare System, University of California San Diego, California, United States of America.
Robert TerkeltaubDepartment of Medicine, Veterans Affairs Healthcare System, University of California San Diego, California, United States of America.ORCID 0000-0001-5368-7473
University of California San Diego · USVictor Chang Cardiac Research Institute · AU

Funding

TISSUE ACQUISITION, MORPHOLOGY, AND CELL CULTUREP01AG007996 · NIA · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI D'LIMA, DARRYL D. · 1989 to 2016
$26.0M
The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SINGH, JASVINDER A · 2012 to 2021
$12.8M
Innate Inflammation in OsteoarthritisI01BX001660 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI TERKELTAUB, ROBERT A. · 2012 to 2020
–
BLRD VA I01 BX001660BLRD VA I01 BX002234NIAMS NIH HHS P50 AR060772NIA NIH HHS P01 AG007996
6 · The paper itself

Abstract

Neointimal hyperplasia, stimulated by injury and certain vascular diseases, promotes artery obstruction and tissue ischemia. In vascular smooth muscle cell (VSMCs), multiple modulators of protein handling machinery regulate intimal hyperplasia. These include elements of the VSMC unfolded protein response to endoplasmic reticulum stress (UPRER), and transglutaminase 2 (TG2), which catalyzes post-translational protein modification. Previous results for deficiency of UPRER-specific mediator XBP1, and of TG2, have been significant, but in multiple instances contradictory, for effects on cultured VSMC function, and, using multiple models, for neointimal hyperplasia in vivo. Here, we engineered VSMC-specific deficiency of XBP1, and studied cultured VSMCs, and neointimal hyperplasia in response to carotid artery ligation in vivo. Intimal area almost doubled in Xbp1fl/fl SM22α-CRE+ mice 21 days post-ligation. Cultured murine Xbp1 deficient VSMCs migrated more in response to platelet derived growth factor (PDGF) than control VSMCs, and had an increased level of inositol-requiring enzyme 1α (Ire1α), a PDGF receptor-binding UPRER transmembrane endonuclease whose substrates include XBP1. Cultured XBP1-deficient VSMCs demonstrated decreased levels of TG2 protein, in association with increased TG2 polyubiquitination, but with increased TG transamidation catalytic activity. Moreover, IRE1α, and TG2-specific transamidation cross-links were increased in carotid artery neointima in Xbp1fl/fl SM22α-CRE+ mice. Cultured TG2-deficient VSMCs had decreased XBP1 associated with increased IRE1α, and increased migration in response to PDGF. Neointimal hyperplasia also was significantly increased in Tgm2fl/fl SM22α-CRE+ mice at 21 days after carotid ligation. In conclusion, a VSMC regulatory circuit between XBP1 and TG2 limits neointimal hyperplasia in response to carotid ligation.

Indexed as

AnimalsCarotid ArteriesCell MovementCell ProliferationDisease Models, AnimalEndoribonucleasesGTP-Binding ProteinsHumansHyperplasiaLigationMaleMiceMice, KnockoutMuscle, Smooth, VascularMyocytes, Smooth MuscleNeointimaEndoribonucleasesErn1 protein, mouseGTP-Binding ProteinsProtein Glutamine gamma Glutamyltransferase 2Protein Serine-Threonine KinasesTransglutaminasesX-Box Binding Protein 1Xbp1 protein, mouse

Identifiers

PMID30943188
PMCPMC6447169
OpenAlexW2927780986

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.